SAN DIEGO and CALGARY, AB, May 16, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Wednesday, May 15, 2024. A total of 41.34% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.


On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:






Patricia Andrews


84.78 %


15.22 %

Deborah M. Brown


74.81 %


25.19 %

Matthew C. Coffey


70.97 %


29.03 %

Angela Holtham


77.53 %


22.47 %

James T. Parsons


74.81 %


25.19 %

Wayne Pisano


72.88 %


27.12 %

Jonathan Rigby


76.81 %


23.19 %

Bernd R. Seizinger


81.49 %


18.51 %

In addition to the election of all nominees listed as directors in the management information circular, dated March 24, 2024, Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at eight and appointing the auditors for the Corporation for the ensuing year.

For more details on the matters covered at the annual meeting, please refer to the Corporation's management information circular available on SEDAR at Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: or follow the company on social media on LinkedIn and on X @oncolytics.

Company Contact

Investor Relations for Oncolytics

Jon Patton

Timothy McCarthy

Director of IR & Communication

LifeSci Advisors




Cision View original content:

SOURCE Oncolytics Biotech® Inc.

Cision View original content: